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Abstract
Drug delivery systems represent a promising strategy to treat cancer and to overcome
the side effects of chemotherapy. In particular, polymeric nanocontainers have attracted
major interest because of their structural and morphological advantages and the variety
of polymers that can be used, allowing the synthesis of materials capable of responding
to the biochemical alterations of the tumour microenvironment. While experimental
methodologies can provide much insight, the generation of experimental data across a
wide parameter space is usually prohibitively time consuming and/or expensive. To
better understand the influence of varying design parameters on the drug release profile
and drug kinetics involved, appropriately-designed mathematical models are of great
benefit. Here, we developed a novel mathematical model to describe drug transport
within, and release from, a hollow nanocontainer consisting of a core and a pH-responsive
polymeric shell. The two-layer mathematical model fully accounts for drug dissolution,
diffusion and interaction with polymer. We generated experimental drug release profiles
using daunorubicin and [Cu(TPMA)(Phenantroline)](ClO4)2 as model drugs, for which
the nanocontainers exhibited excellent encapsulation ability. The in vitro drug release
behaviour was studied under different conditions, where the system proved capable of
responding to the selected pH stimuli by releasing a larger amount of drug in an acidic
than in the physiological environments. By comparing the results of the mathematical
model with our experimental data, we were able to identify the model parameter values
that best-fit the data and demonstrate that the model is capable of describing the
phenomena at hand. The proposed methodology can be used to describe and predict
the release profiles for a variety of drug delivery systems.
Keywords: Drug delivery, nanocontainers, pH-responsive release, mathematical
model, parameter identification, numerical methods.
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1. Introduction
The use of micro- and nano-particles as drug delivery systems is an extensive area of
research, but the full potential of such technology has yet to be realised. There is grow-
ing interest in utilizing hydrogels, polymeric microspheres and nanoparticles as carrier
systems for cell-specific targeting and for ‘smart’ delivery of drugs, with potential ad-
vantages including the reduction in systemic side-effects and an increase in drug efficacy
[1-8].
Since their inception, nanoscale drug delivery systems (DDSs) have represented one
of the most promising strategies to efficiently treat cancer and to overcome the unpleas-
ant side-effects of conventional chemotherapy. The efficacy of cancer drugs is limited in
clinical administration due to their toxicity and poor solubility. Moreover, intravenous
injection and infusion are associated with considerable fluctuation of drug concentra-
tion in the blood. Therefore, the drugs can only be administered over a limited dosage
and time period. The intrinsic ability of DDSs to target tumor tissues and cells relies
on the so-called enhanced penetration and retention (EPR) effect [9]. This is the un-
derlying basis for the employment of DDSs as amelioration for cancer therapy, since it
takes advantage of the unique features of tumor tissues to direct the drug to its target.
Specifically, DDSs targeting cancer should accumulate in tumours precisely because of
the pathophysiological differences between tumor and healthy tissues. Due to overstim-
ulated and defective angiogenesis, tumours have leaky vessels allowing the penetration
of DDSs with compatible size [10]. Also, the inefficient lymphatic drainage guarantees
the retention of the delivery agents and the released drug in the area [11, 12]. Whereas
more conventional drug administration is indiscriminate, nanoscale DDSs are designed
to specifically enter and accumulate into the tumor tissues because of the EPR effect,
where they are meant to release their payload.
The effectiveness of nanoscale polymeric delivery systems can be improved by de-
signing structures capable of responding to specific pre-set conditions by altering their
properties and favoring the release of the loaded drug. Stimuli-responsive nanocontain-
ers are a family of DDSs that can control the release of the therapeutic active agents in
response to external triggers such as temperature, pH, electrical fields and many others.
In particular, when the pore geometry or chemical composition can be altered in re-
sponse to environmental stimuli, the nanocontainer is expected to provide a wide range
of applications because of the selective permeability and controlled release of its cargo
[2] . Therefore, the development of new kinds of environmental stimuli-responsive and
smart drug delivery systems is relevant and highly desirable. They have gained increas-
ing attention recently and many examples can be found in literature [3, 8, 13, 14, 15].
Tumor cells and tissues are characterized by some internal biochemical alterations
that can be used as a trigger for drug release [16, 17]. Among these alterations, the
best known and most exploited one is probably pH. There is a clear difference between
healthy tissues (pH≈ 7.4) and diseased tissues (pH< 6.0 in tumours). Also, intracellular
differences between normal and cancer cells have been highlighted and can be used to
facilitate drug release [3, 18]. At a tissue level, tumours have lower extracellular pH
due to their faster metabolism and lower oxygen content. Lack of oxygen may cause
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Figure 1: 3D representation of a core-shell nanocontainer (figure not to scale).
hypoxia, leading to the production of lactic acid, which in turn reduces pH in the
tissue [17]. At a cellular level, in the endosome-lysosome system, the preferential route
for the internalization, DDSs encounter much lower pH than the neutral extracellular
environment, such as the endosome (pH 5.0–6.0) and lysosomes (pH 4.5–5.0). Lysosomal
pH in cancer has been reported to be as low as 4.0 [19].
Polymers that display a physico-chemical response to stimuli have been widely ex-
plored as potential DDSs [20]. For example, ionizable polymers are optimal candidates
for the synthesis of pH-responsive systems. Weak acids and bases such as carboxylic
acids and amines exhibit a change in the ionization state depending on variation of the
pH, which in turn affects the capability of the DDS to interact with drugs. Therefore,
pH variations can result in breakage of these interactions, facilitating the release of a
loaded drug [21]. Among a variety of DDSs, one of the most promising examples are
core-shell nanocontainers (NCs), due to their ability to carry larger amount of drugs
than other systems [15] . Typically, a core-shell NC consists of a drug-loaded (fluid or
solid) spherical centre (core) coated by a polymeric layer (shell) acting as a protective
barrier against external chemical aggression and mechanical erosion. The core struc-
ture is generally conceived to locate the therapeutic agent, whilst the polymer shell is
designed to control the drug release (Fig. 1). The drug is encapsulated in both com-
partments but the core is known to be extremely important to increase the amount of
loaded drug compared to other systems [22]. Such two-layer assembly allows for better
control of the drug release.
Mathematical and computational (in silico) modelling can provide a better under-
standing of the influence of different design parameters, which may then either be used
to reduce the design space for experiments or, more ambitiously, be utilised as a pre-
dictive screening tool for drug carriers [20, 23, 24]. Numerous mathematical models
have been derived to describe and predict drug release from diffusion controlled-release
3
Figure 2: Chemical structure of CTP (left) and DNR (right).
systems, accounting for the various physical and chemical phenomena that contribute to
the overall drug release kinetics [7, 20, 23]. However, theoretical studies on drug delivery
from pH-responsive systems are relatively scarce. One exception is the study by Manga
et al. [5], who considered the effect of pH on drug release from hydrogels by modelling
a pH-dependent swelling behaviour.
In this paper, we develop a novel mathematical model of drug transport within, and
release from, a drug-loaded NC. The model considers the two distinct layers (core and
shell) and accounts for drug dissolution and diffusion within the core, as well as drug
diffusion and binding within the shell. Several of the models parameters are considered
pH-dependent, enabling the model to account for pH-dependent drug release. The model
is calibrated through comparison of the model results with existing and new experimental
drug release data from pH-sensitive NCs containing two different molecules (Fig. 2): (i)
[Cu(TPMA)(Phenantroline)](ClO4)2 (hereafter referred to as CTP), a highly innovative
metallodrug recently documented for gene therapy [25] (drug release data reported in
[14]) and (ii) the chemotherapeutic agent daunorubicin (DNR) (new drug release data
presented here). While the synthesis of the NC’s has already been reported, the present
study focuses on the release kinetics of these two drugs from the NCs, since DNR is
currently one of the most used chemotherapy agents while CTP is a very promising
candidate for future generation medicine which would greatly benefit from selective
release in the target area [15].
2. Materials and methods
2.1. Synthesis of pH-responsive nanocontainers
The synthesis of the pH-responsive nanocontainers has already been reported [14].
Here we provide a brief summary and point the reader to the supplementary data for
further details. We consider drug release data from a pH-sensitive hollow NC, predomi-
nantly made of methacrylic acid (MAA), the monomer responsible for the pH sensitivity.
The carboxylic groups of the resulting poly methacrylic acid (PMAA) shell can be pro-
tonated or deprotonated depending on the pH, enabling different interactions with the
external environment [26, 27]. To form the shell, we utilised two additional monomers:
N,N-methylenebis(acrylamide) (MBA), used as a cross-linking agent to maintain the
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structure of the hollow NCs in water, and poly(ethylene glycol) methyl ether methacry-
late (PEGMA), which is a hydrophilic, nontoxic component known to show resistance
against nonspecific protein adsorption and to prolong the in vivo residence time of the
DDS [28].
The resulting diameters of the central cavity and of the shell suspended in water
were 0.3µm and 0.55µm, respectively, according to the requirements for such systems.
A relatively constant diameter after long-term storage at room temperature was ob-
served, indicating favorable stability properties. No effects of erosion or degradation
were reported over the time scale considered.
2.2. Drug loading
In the present study we loaded the NCs with DNR, while in a previous study our
model drug was CTP [14]. For DNR loading, 5mg of hollow NCs were suspended in
5ml of phosphate buffer saline (PBS, pH 7.4) with the aid of ultrasonic bathing. 5mg of
daunorubicin hydrochloride (DNR HCl) were then dissolved in the medium. The sus-
pension was covered with foil and maintained under gentle agitation for 72h at r.t. The
non-encapsulated DNR was then removed with 15 cycles of centrifugation/resuspension
(5min × 9000rpm). The encapsulated amount of DNR was indirectly determined by UV
spectroscopy: the total amount of loaded DNR was calculated by the difference between
the amount of DNR in feeding and in the supernatant fractions. These calculations were
based on a standard curve of DNR in PBS and the concentration was determined with
absorbance measurements at 484nm. The drug loading process was evaluated using the
parameters encapsulation efficiency (EE%) and loading capacity (LC%), defined as:
EE%=Encapsulated drug (mg) / drug in feeding (mg) × 100
LC%=Encapsulated drug (mg) /drug loaded into NCs (mg) × 100
For DNR, we obtained EE(%)= 87.1±2.9 and LC(%)= 47.2±0.1, which translates into
an encapsulation of 0.893mg of DNR per 1mg of NC. The loading ability of the hollow
NCs relies on the interactions between the groups of the shell and the drug. Specifically,
electrostatic interaction is the most important one and involves the negatively charged
carboxylic groups of PMAA (pKa ca. 4.5; in the anionic form −COO− in the loading
conditions) and the amino groups of the drug (pKa 8.6 [29]; mostly as −NH3+ in the
loading conditions). Hydrogen bonds also play a crucial role, which involve other non-
ionized functional groups, such as the amide group of the cross-linking agent, PEG chains
and the carbonyl and hydroxyl groups of DNR [30]. The encapsulation process of CTP
(see supplementary material) resulted in encapsulation efficiency and loading capacity
of EE(%)= 36.4 ± 5.2 and LC(%)= 42.0 ± 3.3, respectively, which corresponds to the
encapsulation of 0.724 mg (0.988µmol) of CTP per 1mg of NC [14]. Unlike DNR, CTP
is water-insoluble and adequate aqueous conditions to dissolve the drug and to suspend
the NCs were required. This was achieved by adding 5% of acetronitile to the loading
buffer (PBS). The main interaction involved in the encapsulation of CTP is probably
electrostatic between the negatively charged carboxylate anions of PMAA and the 2+
positive charge of Cu, which the complex assumes upon dissolution of the perchlorate
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counterions. In addition, in view of previously-reported data on this molecule, a distal
pyridine nitrogen donor atom of TMPA was identified within the coordination complex
and may therefore interact with the NCs through hydrogen bonding [25].
2.3. In vitro drug release studies
The pH sensitivity of the system was tested by means of in vitro drug release experi-
ments. For the DNR experiments, 1mg of DNR-loaded NCs were suspended in 0.5ml of
buffer and loaded into MWCO 140 kDa dialysis tube and incubated in 50ml each buffer
solution. Three different pH conditions were used for the analysis of release: citrate
buffer 0.1M pH 4.0 – 5.5 and PBS 1× pH 7.4. At different time points (30min, 1h, 2h,
5h, 8h, 10h, 24h, 48h, 72h), 1ml of the solutions was withdrawn and analyzed. The
concentration of each sample, and therefore of the release medium at each time point
was determined with UV spectroscopy by using the standard curve method (at 484
nm). A standard curve of DNR was recorded in each buffer used as a release medium.
The experiment was carried out three times for statistical analysis. For details of the
CTP drug release study that we previously reported [14], we refer the reader to the
supplementary material.
3. Mathematical modelling
3.1. Modelling drug release from core-shell nanocontainers
Our previous study on CTP release from the NCs revealed that the amount of drug
released varies depending on the pH of the environment. The CTP release profile from
the NCs was studied in both acidic and slightly basic environments. After 24h, the
amount of drug released was, respectively, 50% and 32% [14]. The carboxylic groups of
PMAA are the key for the interpretation of these results. They are mostly protonated
at pH 4.0 and they cannot interact with the positively charged CTP complex, causing
the release. In addition, it is known that at pH 4.0, the hydrogen-bonding interactions
are weaker than in neutral conditions, thus facilitating the release [3]. Motivated by
these findings, here we develop a reaction-diffusion continuum model to describe drug
(either CTP or DNR) transport within, and release from, the drug-loaded NCs under
different pH conditions. We restrict our attention to modelling in vitro drug release so
that we may effect comparison with our experimental data. We note that no significant
degradation of the NCs was observed over the course of the in vitro experiments.
We start by considering a single NC as a two-layer spherical system, comprising an
internal core Ω0 and the enveloping concentric shell Ω1. Let us denote by R0 and R1
the internal and external radius of the NC, with the origin located at the centre of the
NC and the r-axis oriented with the positive direction pointing outwards (Fig. 3). In
what follows, the subscripts 0 and 1 indicate parameters and variables referring to the
core and shell layer, respectively. Due to the homogeneity and isotropy of each layer, we
can assume that net drug diffusion occurs along the radial direction only, and thus we
restrict our study to a one-dimensional model that reflects a perfectly radially symmetric
system.
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Figure 3: Schematic representation of a cross-section of the two-layer NC, comprising an internal core
Ω0 and an external shell Ω1 (figure not to scale).
The majority of the drug is contained within the core, and we assume an initially ho-
mogeneous distribution of drug within this region, at some concentration B0. However,
the particle preparation methods may also result in some drug mass being contained
with the shell initially. We assume that this drug, of concentration B1, is permanently
encapsulated and may never be released. When exposed to the release medium, the NC
uptakes water and a dissolution process ensues, converting immobile (undissolved) drug
of concentration b0(r, t) in the core to dissolved drug of concentration c0(r, t). Follow-
ing our previous work [31], we model dissolution as a nonlinear process whereby drug
dissolves at a rate β and in proportion to the difference between the dissolved drug con-
centration and the solubility of the drug in the medium, S. The 2/3 exponent accounts
for potential influences on the dissolution rate as the surface area of the dissolving drug
particles changes [32]. When dissolved, the drug is able to diffuse through the core with
diffusion coefficient D0. The dynamics of drug dissolution and diffusion in the core is
then described by the following two partial differential equations:
∂b0
∂t
= −βb2/30 (S − c0) ,
∂c0
∂t
= D0
(
∂2c0
∂r2
+
2
r
∂c0
∂r
)
+ βb
2/3
0 (S − c0) , in (0, R0). (3.1)
Our experiments clearly show that a pH-dependent fraction of the initial drug loading
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is retained within the NCs and is never released. We model this observed phenomenon
through first order reaction kinetics, whereby drug diffusing through the polymeric shell
has the possibility to permanently bind to the polymeric shell at a rate k. We note
that other forms of interaction could have been considered: in this study, however, we
chose to focus on a simple linear reaction model in the absence of evidence to suggest
otherwise. Drug that is able to traverse the full radius of the shell is rapidly cleared due
to the sink conditions imposed in the experiment. Denoting by b1(r, t) and c1(r, t) the
bound and unbound phase concentrations, respectively, the drug dynamics in the shell
are then governed by the following equations [31]:
∂c1
∂t
= D1
(
∂2c1
∂r2
+
2
r
∂c1
∂r
)
− kc1
∂b1
∂t
= kc1 in (R0, R1), (3.2)
where D1 represents the diffusion coefficient of the drug in the shell. To close the sys-
tem (3.1)–(3.2), we are required to impose appropriate boundary and initial conditions.
At the interface between the core and shell layers, we assume continuity of flux and
concentration:
−D0∂c0
∂r
= −D1∂c1
∂r
, c0 = c1 at r = R0. (3.3)
For radial symmetry we require:
∂c0
∂r
= 0 at r = 0. (3.4)
At the NC surface, we impose a perfect sink condition because of the relatively large
size of the release medium and well stirred conditions:
c1 = 0, at r = R1, (3.5)
At initial time, the drug is loaded in the core at concentration B0, while the shell contains
bound drug at concentration B1:
b0 = B0, c0 = 0 b1 = B1 c1 = 0 (3.6)
The total mass of drug within the NC at any time is given by integrating the con-
centration of drug within each phase and layer over the corresponding volume [31], that
is
Mtot(t) = 4pi
 R0∫
0
r2 {b0(r, t) + c0(r, t)} dr +
R1∫
R0
r2 {b1(r, t) + c1(r, t)} dr
 (3.7)
The drug release profile, Mrel(t), defined as the cumulative % of drug released by time
t, is then given by
%Mrel(t) =
Mtot(0)−Mtot(t)
Mtot(0)
× 100, (3.8)
where Mtot(0) is the total initial mass of drug in the NC.
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3.2. Solution method
Before solving the model (3.1)–(3.6) numerically, it is convenient first to nondimen-
sionalise the equations. We scale r with the radius of the shell and scale t with the
timescale for diffusion in the shell:
r → r
R1
, t→ D1
R21
t. (3.9)
Scaling all concentrations with B0, the model may then be written in terms of five
non-dimensional groups:
D =
D0
D1
, Da =
βB
2/3
0 R
2
1
D1
, k˜ =
kR21
D1
, S˜ =
S
B0
, B˜1 =
B1
B0
, (3.10)
where Da may be regarded as a Damko¨hler number, defined as the ratio of dissolu-
tion rate to diffusion rate, and k˜ denotes the ratio between the binding rate and rate
of diffusion in the shell. The nondimensional system of six equations were then dis-
cretized spatially before solving the resulting system of ordinary differential equations,
following the method we previously described [31] (for further details please refer to the
supplementary material).
3.3. Optimization strategy
As in many biological systems, the model contains a number of parameters: many
of these are not known a priori, and those that have been measured are often subject
to high variability and uncertainty. Obtaining reliable estimates of parameters is a
significant challenge in the field. Starting from a physically realistic range of parameters
(Table 1), we address this issue here by an optimization strategy. Specifically, using
the experimental data points, we inversely estimate the five unknown nondimensional
parameters (3.10) of the model for each pH, such that the model solution best fits the
data for each drug. We employ an optimization method based on an objective function
subject to a number of constraints (due to physical and experimental conditions) over a
set of experimental data. We proceed first with a direct search based on a standard least
squares approach and then refine with a pattern-search algorithm. For further details,
we refer the reader to the supplementary material.
4. Results and discussion
4.1. DNR In vitro drug release
The results of our in vitro DNR release study clearly show, similarly to CTP, that the
amount of drug released varies depending on the pH of the environment. This behavior
can be explained by considering the interaction between DNR and the carboxylic groups
of the NCs. At physiological pH (7.4) the carboxylic groups of PMAA are deprotonated
and interact with the protonated amino group of DNR (pKa 8.6) favoring the retention
of the drug in the NCs (also encapsulation conditions). At pH 5.5, a lower percentage of
carboxylic groups are protonated, which causes a decrease in the number of interactions
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Table 1: Possible range of the nondimensional parameters considered in optimization algorithm. These
ranges were chosen based on physical constraints and typical values, and span at least 3 orders of
magnitude for each parameter.
Parameter Min. Max.
D 2 103
Da 10−1 102
S˜ 10−2 102
k˜ 10−2 102
B˜1 10
−3 10
Table 2: Optimal nondimensional parameters at three values of pH for DNR.
Parameter pH=4 pH=5.5 pH=7.4
1 D 35.60 61.50 113.05
2 Da 0.63 0.96 1.10
3 S˜ 2.64 3.35 5.60
4 k˜ 0.47 4.65 10.89
5 B˜1 0.12 0.12 0.12
DDS-DNR and, as a consequence, a larger amount of drug is released. At pH 4.0
the majority of the carboxylic groups are protonated, therefore there will be fewer
electrostatic interactions and the drug will be more easily released than in the two
previously-described conditions.
4.2. Drug release simulation
The results of our parameter identification procedure are detailed in Table 2 and
Table 3 for the drugs DNR and CTP, respectively. For DNR we observe an increase in
the value of four of the non-dimensional parameters (D, Da, S˜ and k˜) with increasing
pH, over the values of pH studied in the experiments (Fig. 4). The value of B˜1,
however, remains constant since this is simply the ratio of initial drug concentration
in the shell normalised by the initial drug concentration in the core and is a function
of the fabrication process rather than the pH. Within the supplementary material, we
explain in detail how this parameter is obtained as part of the inverse problem. Similar
trends are observed for CTP for the parameters D, Da and k˜ (Fig. 4). However,
for CTP, the normalised solubility S˜ decreases with increasing pH, according to what
expected due to the complete protonation of amine and pyridine nitrogens at low pH.
An interesting result from Tables 2-3 is the monotonicity of the parameters with pH.
The order of magnitude of the parameters for DNR and CTP is the same: due to the
extremely large space of parameters, this is an indirect confirmation of the correctness
of the optimization procedure.
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Table 3: Optimal nondimensional parameters at two values of pH for CTP.
Parameter pH=4 pH=7.4
1 D 48.59 86.91
2 Da 0.14 0.67
3 S˜ 2.20 0.11
4 k˜ 0.09 6.31
5 B˜1 0.18 0.18
In Figures 5-6 we show the experimental drug release data for DNR and CTP. The
curves correspond to the solution of the model obtained with the optimal parameters
for the values of pH studied. Clearly, the release of each drug is well-captured by the
two-phase two-layer dissolution-diffusion-reaction model that we have devised. Probing
further, we are able to establish that the slower release of DNR with increasing pH is
likely as a result of a slower diffusion coefficient in the shell, coupled with faster binding
to components of the shell. As a result, as the pH is increased, a greater fraction of
the initial drug load is permanently retained and never released. For CTP, the picture
is a little more complicated. Firstly, the decrease in solubility with pH has the effect
of slowing the dissolution process. However, there is a modest increase in diffusion
coefficient within the shell with pH, which coupled with the the simultaneous increase
in binding within the shell results in a k˜ that greatly exceeds 1, indicating that binding
is dominating and transport within the shell is increasingly diffusion-limited.
Our mechanistic model confirms a pH-responsiveness of the PMAA shell in a manner
that is dependent on the particular drug studied. For DNR we observe an increasingly
pronounced delay in drug-release with pH, likely corresponding to the slower diffusion
coefficient and faster binding in the shell with pH, as described above. This effect is
significantly less for CTP, where we observe an “initial burst” of drug, particularly for
the lowest value of pH, which may be beneficial if an immediate and fast deliver of drug is
desired, as in presence of cancer cells. The implication is that, while for targeting cancer
the biological effect of the drug is important, the release kinetics of the drugs can vary
depending on their chemical-physical properties and interaction with polymer, meaning
that both aspects have to be considered hand-in-hand when choosing an appropriate
drug to load the NC.
4.3. Limitations
We would like to emphasize that there are limitations in this work. The mathemat-
ical model makes a number of assumptions as detailed in the text and the experimental
data have been obtained in an in vitro environment. Importantly, while we have demon-
strated that a dissolution-diffusion-reaction mechanism captures the drug release well,
the different identified model parameters for different values of pH points to a complex
relationship between pH and the various drug-transport parameters. In this preliminary
study, we have not sought to identify the particular functional dependence of the vari-
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Figure 4: Variation of the five nondimensional parameters vs pH.
ous parameters on pH, and this is left for future work. Notwithstanding, the approach
adopted here of identifying these parameters computationally on a small set of in vitro
data is still very useful, since once calibrated the model can be used in a predictive
sense to reduce the number of in vitro experiments, and with further modification, can
be correlated with in vivo data.
5. Conclusions
Nanocontainers made of pH-responsive polymers are of technological interest and
have many potential applications in medicine, including their use as controlled DDSs.
They have attracted great attention as potential drug carriers and offer significant ad-
vantages over more traditional therapies, both in terms of efficacy and safety. We have
shown that a pH sensitive controlled-drug releasing NC is well described by a dissolution-
diffusion-reaction core-shell mathematical model.
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Figure 5: Best fitting release curves vs. experimental data for DNR at pH=4, 5.5 and 7.4.
Figure 6: Best fitting release curves vs. experimental data for CTP at pH=4 and 7.4. (experimental
data taken from [14]).
A number of release experiments involving dispersed NCs of identical size and initial
loaded drug have been carried out and the data have been used to inversely estimate the
best-fitting parameters of the model for each pH studied. The different physico-chemical
characteristics of the two drugs affect their interactions with the pH-sensitive NCs that
in turn, influences the release performance. This is reflected through the parameters of
the mathematical model. Once these parameters have been computationally identified,
the proposed methodology provides a simple tool that can be used to quantitatively
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characterize the drug kinetics, improve the technological performance and optimize the
release rate for the target application. Our combined in vitro experimental and math-
ematical modelling framework may be used to predict NC drug release performance,
opening up the possibility of an in silico approach to optimising the drug release profile
and ultimately the effectiveness of these devices.
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Appendix A. Supplementary data
Appendix A.1. Numerical discretization
The nondimensional model is given by:
∂b0
∂t
= −Da b2/30
(
S˜ − c0
)
in (0, R0), (A.1)
∂c0
∂t
= D
(
∂2c0
∂r2
+
2
r
∂c0
∂r
)
+Da b
2/3
0
(
S˜ − c0
)
, in (0, R0), (A.2)
∂c1
∂t
=
∂2c1
∂r2
+
2
r
∂c1
∂r
− k˜c1 in (R0, 1), (A.3)
∂b1
∂t
= k˜c1 in (R0, 1), (A.4)
∂c0
∂r
= 0 at r = 0, (A.5)
−D∂c0
∂r
= −∂c1
∂r
, c0 = c1 at r = R0, (A.6)
c1 = 0, at r = 1. (A.7)
We proceed to solve the system of equations (A.1)-(A.7) numerically, building on the
method we described previously [31]. Let us subdivide the interval (0, R0) into N + 1
equispaced grid nodes, and the interval (R0, 1) into M+1 equispaced points, with h0 and
h1 the spacing in the core and shell layers, respectively. Let us indicate by a superscript
j the approximated value of the concentrations at rj. In each layer, we approximate
the diffusive terms by considering a standard second order central difference in space
of the second derivative at internal nodes. The reaction terms in eqn. (A.1)-(A.4) do
not contain any spatial derivatives and therefore are evaluated pointwise. For example,
(A.2) is discretized at node rj as:
dc0
dt
∣∣∣∣
rj
= D
cj−10 − 2cj0 + cj+10
h20
+Da (bj0)
2/3(S˜ − cj0). (A.8)
After spatial discretization, the system of PDEs reduces to a set of nonlinear ordinary
differential eqns. of the form:
dY
dt
= A(Y ), (A.9)
where Y = (b00, ...., b
N−1
0 , c
0
0, ...., c
N−1
0 , c
1
1, ..., c
M
1 , b
1
1, ....b
M
1 )
T and A(Y ) contains the dis-
cretized eqns. (A.1)-(A.4) and related boundary/interface conditions (A.5)-(A.7) . The
system (A.9) is solved by the routine ode15s of Matlab based on a Runge-Kutta type
method with backward differentiation formulas, and an adaptive time step [31].
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Appendix A.2. Parameter identification
The mathematical model described in Section 3 and its successful use relies on the
knowledge of the physico-chemical parameters. Unfortunately, the determination of
these quantities by means of experiments is impractical and often associated with large
error. As a consequence, we derive the unknown parameters by solving an inverse
problem: the experimental data are compared with the prediction of numerical model,
and the parameters are used as independent variables to minimize the distance between
the experimental data and the numerical prediction. An optimization problem is then
formulated: given Ns experimental samples Xi = X(ti) (drug released) measured at
different times ti, we define our objective function by a least square method:
F (ξ) =
Ns∑
i=1
(Xi − xi(ξ))2
where xi(ξ) correspond to the computed quantities, depending on the unknown param-
eter set ξ. Then, we can minimize F subject to a number of constraints and ξ in a
given range. Due to the large range investigated, some combinations of the parameters
could be physically unrealistic, and consequently produce unphysical results that should
be discarded. To address this, two different constraint functions are adopted here, the
first related to the released mass, that cannot be negative, and the second enforced on
the positiveness of the first derivative of the drug release curve, since a negative first
derivative would imply that released drug re-enters the NC. Unfortunately, the space
of the parameters ξ is very large: this poses some further difficulties in the optimiza-
tion problem, increasing also the number of areas where the design parameters produce
good values of F (ξ). Taking account of the aforementioned difficulties, we developed an
algorithm as described below.
For each pH we have a different objective function, and different optimization prob-
lems have to be solved, one for each dataset. This results in a set of optimal design
parameters for each value of pH, except for B˜1 that is the ratio of the initial concentra-
tion of drug in the shell to that in the core. Due to the uncertainties on the range ξ,
in a first stage this feature will not be considered, and the optimization problems are
solved independently for each pH, allowing a variation of B˜1 with pH. Once the opti-
mal values for each pH are available, we select a sub-range of B˜1 where the objective
function is satisfactory for all pH, and a unique value of B˜1 is selected accordingly. The
optimization problems are solved again, detecting the optimal values at each pH and
with a common value of B˜1. Finally, a local optimization is performed in order to verify
the correctness of the choice of B˜1.
The first two steps, where a wide range of parameters is investigated, are resolved
by using a Direct Search global optimization algorithm, while the last step is performed
by using a local minimizer.
Direct search
As a first step, a sensible range is defined for five different parameters (3.10) (table
1). The adopted search algorithm is the Parameter Space Investigation (PSI) [33]: some
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sample configurations are uniformly distributed into the design variable space and then
evaluated. The uniformity of the distribution of samples is very important since, at
the beginning, every part of the variable space has the same probability to contain the
global optimum. The search is then concentrated in the neighbourhood of the current
best configuration. In order to reduce the number of samples preserving the uniformity
of the search, an Uniformly Distributed Sequence (UDS) is adopted [34] and is applied
for the selection of the candidates. This class of distribution is designed in order to
produce a sequence of equally-spaced points. The search is executed in parallel, so that
the overall computational time is further reduced.
Due to the wide range of parameters, they are uniformly distributed on a logarithmic
scale. In this way, their order of magnitude is more easily detected. We use a relatively
high number (1024) of samples (not changed along the iterations) to avoid the situation
where certain basins of attraction are neglected. Once all the configurations have been
computed, the successive area of investigation is represented by the subspace including
the five best locations previously detected. The use of more than a single point is
suggested because at the initial stage of the search we have a rather crude analysis of
the variable space, so that one could be distracted by a promising point (i.e. a local
minimizer) that cannot be further improved, discarding the basin of attraction of the
global minimum. This procedure is repeated ten times, providing a successive refinement
of the feasible area. In the second step, PSI is repeated with the same configuration as
before, but with a fixed averaged value of B˜1.
Local optimization
A pattern-search algorithm [35] is adopted for the fine tuning of B˜1. Here the total
number of parameters is four for each value of the pH plus B˜1, that remains the same
for all pH values considered.
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Appendix A.3. Experimental Methods
Synthesis and Characterization of pH-sensitive hollow nanocontainers
The synthesis and the characterization of this drug delivery system has already been
reported elsewhere by some of us [14]. Specifically, the synthesis of the pH-sensitive NCs
consists of three separate steps: the formation of the sacrificial cores, the synthesis of
the shell and the removal of the cores to yield the hollow NCs.
PMAA cores: MAA (2.1 g; 24.4 mmol) was dissolved in 200mL of ACN and
stirred at 75◦C for 30min under nitrogen atmosphere, then AIBN (0.3 g; 1.8 mmol) was
added and the flask content turned from colorless to a milky suspension. Afterward, the
temperature was raised to (95 − 100)◦C to start the distillation. Once 20 mL of ACN
were distilled out, the reaction was stopped. The final product was obtained after three
cycles of centrifugation and resuspension in ACN (5min × 8000rpm).
Shell: 0.15g of PMAA cores were suspended in 200mL of ACN and stirred at 75◦C
for 30min under nitrogen atmosphere. MAA (0.53 g; 6.1 mmol) was then added, and,
after 10 min, PEGMA (0.16g; 0.3 mmol; 5mol % of MAA) and MBA (0.15 g; 0.97 mmol;
16 mol % of MAA) were added as well. After 30min, AIBN (0.09g; 0.5 mmol; 8mol %
of MAA) was added. After 10min, the temperature was raised to (95− 100)◦C to start
the distillation. Once 30 mL of distilled ACN was collected, the reaction was stopped.
The final product was obtained after three cycles of centrifugation and resuspension in
ACN (5min × 5000rpm).
Core removal: 250mg of core-shell structures were suspended in 200mL of a mixture
of 1:1 (v/v) EtOH/H2O and stirred at room temperature overnight. The product was
purified by three cycles of centrifugation and resuspension (5min × 5000 rpm).
Instruments: NC pictures were taken with scanning electron microscopy (SEM)
with W (tungsten) filament operating at 25 kV (Fig. A.7). The hydrodynamic diameter
and the ζ potential of the NCs in distilled water were measured with DLS (Malvern In-
struments Series, nano-ZS with multipurpose titrator). The concentration of the sample
was 0.1mg/mL, and the given results were the average value of 10 measurements, with
20s integration time. FT-IR spectra were recorded with a PerkinElmer Precisely Spec-
trum 100 spectrometer. Sonication was performed with an ultrasonic bath (Elmasonic
S 30H).
CTP Drug Loading
1 mg of NCs was suspended in 950 mL of phosphate-buffered saline (PBS 1×) with
the aid of ultrasonic bathing. 2 mg of CTP previously solubilized in 50 mL of ACN
were then added to the suspension. The final loading medium, containing 1 mg of NCs
and 2 mg of CTP in 1 mL of mixture of PBS/ACN 5% v/v, was kept under gentle
magnetic stirring for 24h at r.t. The non-encapsulated portion of CTP was removed
with five cycles of centrifugations and resuspensions in a fresh mixture PBS/ACN (5
min × 11000 rpm). The amount of encapsulated CTP was indirectly determined by UV
spectroscopy and calculated by the difference of concentration between the original CTP
solution and the supernatants containing the non-encapsulated drug. The calculations
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Figure A.7: SEM image of pH-sensitive NCs siepmann3
were based on a calibration curve of CTP obtained in the same solvent mixtures with
absorbance measurements at 262 nm [14].
CTP in vitro drug release study
1 mg of CTP-loaded NCs was suspended in distilled water, split into two dialysis
bags, and incubated in 25 mL of each release medium: citrate buffer 0.1M + 5% ACN
pH4.0 and PBS 1× + 5% ACN pH 7.4. At different time points (as above), 1 mL was
collected from each solution and the concentration of the samples was measured using
UV spectroscopy. The calculations were made upon a calibration curve of CTP recorded
in each buffer (at 262 nm). The experiment was carried out three times for statistical
analysis [14].
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